Magicine Pharma

Select Location

Bdparp 100mg Tablet
Bdparp 100mg Tablet

Bdparp 100mg Tablet

4.8
Google Rating

Prescription Required

Marketed By

bdr pharma

Pack of

28 Tablets in Bottle

Salt Composition

Olaparib

Storage

keep in cold place

Contact for Price

Bdparp 100mg Tablet

Bdparp 100mg Tablet

Contact for Price
shipping-zone

Delivering To: —

Overview

Bdparp 100mg tablet contains olaparib, which belongs to the antiviral drug category polyadenosine diphosphate-ribose polymerase (PARP). In cancer cells multiply in an uncontrolled manner. This tablet is used for treating prostate and pancreatic cancer; it can be given alone or in combination with other anticancer medications.

Indication

Ovarian Cancer, Breast Cancer

UsesBenefitsSide EffectsHow To UseHow It WorksSafety AdviceMissed DosesQuick TipsFAQsReference

Uses

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet, 376(9737), 245-251.

Guo, X. X., Wu, H. L., Shi, H. Y., Su, L., & Zhang, X. (2024). The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N. & Carmichael, J. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244.

van der Noll, R., Jager, A., Ang, J. E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J. S., & Schellens, J. H. (2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs, 38(4), 1096-1107.

Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T. (2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer science, 103(3), 504-509.

Benefits

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet, 376(9737), 245-251.

Guo, X. X., Wu, H. L., Shi, H. Y., Su, L., & Zhang, X. (2024). The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N. & Carmichael, J. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244.

van der Noll, R., Jager, A., Ang, J. E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J. S., & Schellens, J. H. (2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs, 38(4), 1096-1107.

Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T. (2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer science, 103(3), 504-509.

Side Effects

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet, 376(9737), 245-251.

Guo, X. X., Wu, H. L., Shi, H. Y., Su, L., & Zhang, X. (2024). The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N. & Carmichael, J. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244.

van der Noll, R., Jager, A., Ang, J. E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J. S., & Schellens, J. H. (2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs, 38(4), 1096-1107.

Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T. (2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer science, 103(3), 504-509.

How To Use

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet, 376(9737), 245-251.

Guo, X. X., Wu, H. L., Shi, H. Y., Su, L., & Zhang, X. (2024). The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N. & Carmichael, J. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244.

van der Noll, R., Jager, A., Ang, J. E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J. S., & Schellens, J. H. (2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs, 38(4), 1096-1107.

Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T. (2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer science, 103(3), 504-509.

How It Works

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet, 376(9737), 245-251.

Guo, X. X., Wu, H. L., Shi, H. Y., Su, L., & Zhang, X. (2024). The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N. & Carmichael, J. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244.

van der Noll, R., Jager, A., Ang, J. E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J. S., & Schellens, J. H. (2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs, 38(4), 1096-1107.

Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T. (2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer science, 103(3), 504-509.

Safety Advice

Alcohol

Alcohol

consult your doctor

Drinking too much alcohol could damage a person's immunity and liver function. Alcohol consumption can cause dizziness, confusion, tiredness, and cognitive impairment, so it is advised not to consume alcohol while taking the Bdparp 100mg tablet.
Pregnancy

Pregnancy

consult your doctor

It is not advised to take the Bdparp 100mg tablet when pregnant because it affects the fetus. This is not for use in pregnant women.
Breast Feeding

Breast Feeding

consult your doctor

Because there is a possibility that the Bdparp 100 mg tablet could be transferred to the developing infant through the mother's breast milk, it is not advised to consume it while nursing. It is widely regarded as dangerous, and there is not enough evidence in the clinical data on its adverse impacts on infants.
Driving

Driving

unsafe

Taking a Bdparp 100 mg tablet while operating machinery may cause confusion or impair one's driving capacity. The capsule may cause neurological side effects, such as fever or feeling dizzy. Until you feel better, don't drive.
Kidney

Kidney

safe if prescribed

People with kidney issues can use the Bdparp 100 mg tablet after consulting with the doctor. It may harm the kidneys if taken as self-medication
Liver

Liver

safe if prescribed

People with severe liver illness should not use the Bdparp 100 mg tablet. Whereas people with mild liver disease can use this solution, but it must be regularly monitored. Use caution and alter the dosage of the Bdparp 100 mg tablet as advised by your doctor.

Missed Doses

Quick Tips

FAQs

Bdparp 100 mg tablets are used for which purposes?

Bdparp 100 mg tablet is used for the treatment of breast, ovarian, prostate, and pancreatic cancer.

How does the Bdparp 100 mg tablet work in the body?

Bdparp 100mg tablet works by blocking the repair mechanism of DNA; as a result, the growth of cancer cells stops. The tablet inhibits PARP (poly-ADP-ribose polymerases), which belongs to the family of proteins that play an important role in genomic stability, DNA repair, and cellular stress responses. The enzymes repair the single-strand DNA breaks (SSBs). Bdparp 100 mg tablet inhibits the working of PARP enzymes, which hinders the growth and development of cancer cells.

If a person has low white blood cells (neutropenia), can they take a Bdparp 100 mg tablet?

A person with low white blood cells is advised to consult the doctor first before taking the Bdparp 100 mg tablet, as this drug can also cause neutropenia.

I forgot to take the Bdparp 100 mg tablet. What to do?

As soon as you remember, take the missed dose unless it's time for your next dose. You should never take a double dose to make up for a missed one.

What are the side effects of the Bdparp 100 mg tablet?

Common side effects of the Bdparp 100 mg tablet are constipation, muscle pain, swelling, nausea, diarrhea, infection, loss of appetite, hair loss, vomiting, and weakness.

How long does the treatment with the Bdparp 100 mg tablet last?

The doctor decides how long the treatment with the Bdparp 100 mg tablet will continue, depending on the stage and health of the patient

Can I drink alcohol while taking the Bdparp 100 mg tablet?

    It is advised not to take alcohol while taking the Bdparp 100mg tablet, because consuming alcohol can cause serious side effects and can damage your liver badly. Consult your doctor if you have concerns or queries.

Is it safe to take this Bdparp 100 mg tablet during pregnancy or breastfeeding?

During pregnancy, it is not safe to take Bdparp 100 mg tablets, as they can cause harm to the unborn baby. Furthermore, during breastfeeding, this medicine must not be used. Please make sure to consult your healthcare provider regarding the same.

Reference

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet, 376(9737), 245-251.

Guo, X. X., Wu, H. L., Shi, H. Y., Su, L., & Zhang, X. (2024). The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N. & Carmichael, J. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244.

van der Noll, R., Jager, A., Ang, J. E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J. S., & Schellens, J. H. (2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs, 38(4), 1096-1107.

Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T. (2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer science, 103(3), 504-509.

Ratings And Reviews

4.8
Google Rating

4.33/5

3 Ratings

5

33.33%

4

66.67%

3

0.00%

2

0.00%

1

0.00%

Isabella Martinez

Good quality for the price

Good experience with Bdparp 100mg Tablet. The product works well and quality is satisfactory. Delivery was on time and packaging was good. Would recommend to others. Packaging was secure and delivery was quick.

9 months ago

Riya Shah

Perfect for my needs

I've been using Bdparp 100mg Tablet for a few weeks now and I'm really impressed. The quality is excellent and it works exactly as expected. The packaging was secure and delivery was prompt. Highly recommend this product!

9 months ago

View All Reviews

Related Products

Reglid 120mg Tablet

Reglid 120mg Tablet

Contact for Price
Ribaxa Plus 100mg Tablet

Ribaxa Plus 100mg Ta...

Contact for Price
Hertab 250mg Tablet

Hertab 250mg Tablet

Contact for Price
Lippod 20mg Injection

Lippod 20mg Injectio...

Contact for Price
Enzamide 80mg Capsule

Enzamide 80mg Capsul...

Contact for Price
Dasamed 50mg Tablet

Dasamed 50mg Tablet

Contact for Price

MARKETER DETAILS

bdr pharma

DISCLAIMER

The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.

Home

Categories

Brands

Account